Management of Ground-glass Opacities: Should All Pulmonary Lesions with Ground-glass Opacity Be Surgically Resected?

Overview

Journal Transl Lung Cancer Res

Date 2015 Mar 26

PMID 25806254

Citations 57

Authors

Yoshihisa Kobayashi

Tetsuya Mitsudomi

Affiliations

Soon will be listed here.

Abstract

Pulmonary nodules with ground-glass opacity (GGO) are frequently observed and will be increasingly detected. GGO can be observed in both benign and malignant conditions, including lung cancer and its preinvasive lesions. Atypical adenomatous hyperplasia and adenocarcinoma in situ are typically manifested as pure GGOs, whereas more advanced adenocarcinomas may include a larger solid component within the GGO region. The natural history of GGOs has been gradually clarified. Approximately 20% of pure GGOs and 40% of part-solid GGOs gradually grow or increase their solid component, whereas others remain unchanged for years. Therefore, it remains unclear whether all pulmonary lesions with GGO should be surgically resected or whether lesions without changes may not require resection. To distinguish GGOs with growth from those without growth, a 3-year follow-up observation period is a reasonable benchmark based on the data that the volume-doubling time (VDT) of pure GGOs ranges from approximately 600 to 900 days and that of part-solid GGOs ranges from 300 to 450 days. Future studies on the genetic differences between GGOs with growth and those without growth will help establish an appropriate management algorithm.

Citing Articles

Predicting malignant risk of ground-glass nodules using convolutional neural networks based on dual-time-point F-FDG PET/CT.

Liu Y, Wang J, Du B, Li Y, Li X Cancer Imaging. 2025; 25(1):17.

PMID: 39966960 PMC: 11837479. DOI: 10.1186/s40644-025-00834-8.

Acquisition of discrete immune suppressive barriers contributes to the initiation and progression of preinvasive to invasive human lung cancer.

Yoffe L, Bhinder B, Kang S, Zhang H, Singh A, Ravichandran H bioRxiv. 2025; .

PMID: 39803458 PMC: 11722343. DOI: 10.1101/2024.12.31.630523.

Precise diagnosis and prognosis assessment of malignant lung nodules: a narrative review.

Wen M, Zheng Q, Ji X, Xin S, Zhou Y, Tian Y J Thorac Dis. 2024; 16(11):7999-8013.

PMID: 39678870 PMC: 11635230. DOI: 10.21037/jtd-24-1058.

Multiomics Analysis Reveals Molecular Changes during Early Progression of Precancerous Lesions to Lung Adenocarcinoma in Never-Smokers.

Chen Y, Hsu C, Wang H, Wu S, Chang Y, Chen J Cancer Res. 2024; 85(3):602-617.

PMID: 39570802 PMC: 11786955. DOI: 10.1158/0008-5472.CAN-24-0821.

A Novel Scale for Diagnosis of Pulmonary Ground-Glass Nodules: A Multicenter and Ambispective Cohort Study.

Yu M, Cheng Y, Wen T, Zhang L, Wei X, Wang Y Clin Respir J. 2024; 18(11):e70027.

PMID: 39520253 PMC: 11549650. DOI: 10.1111/crj.70027.

References

Kim H, Choi Y, Kim J, Shim Y, Lee K, Kim K . Management of multiple pure ground-glass opacity lesions in patients with bronchioloalveolar carcinoma. J Thorac Oncol. 2009; 5(2):206-10. DOI: 10.1097/JTO.0b013e3181c422be. View

Suzuki K, Koike T, Asakawa T, Kusumoto M, Asamura H, Nagai K . A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol. 2011; 6(4):751-6. DOI: 10.1097/JTO.0b013e31821038ab. View

Kodama K, Higashiyama M, Takami K, Oda K, Okami J, Maeda J . Treatment strategy for patients with small peripheral lung lesion(s): intermediate-term results of prospective study. Eur J Cardiothorac Surg. 2008; 34(5):1068-74. DOI: 10.1016/j.ejcts.2008.07.044. View

Nakata M, Sawada S, Yamashita M, Saeki H, Kurita A, Takashima S . Objective radiologic analysis of ground-glass opacity aimed at curative limited resection for small peripheral non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005; 129(6):1226-31. DOI: 10.1016/j.jtcvs.2004.10.032. View

Suzuki K, Kusumoto M, Watanabe S, Tsuchiya R, Asamura H . Radiologic classification of small adenocarcinoma of the lung: radiologic-pathologic correlation and its prognostic impact. Ann Thorac Surg. 2006; 81(2):413-9. DOI: 10.1016/j.athoracsur.2005.07.058. View

Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S . Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995; 75(12):2844-52. DOI: 10.1002/1097-0142(19950615)75:12<2844::aid-cncr2820751209>3.0.co;2-#. View

Hansell D, Bankier A, MacMahon H, McLoud T, Muller N, Remy J . Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008; 246(3):697-722. DOI: 10.1148/radiol.2462070712. View

Lee H, Kim Y, Kang C, Zhao B, Tan Y, Schwartz L . Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. Radiology. 2013; 268(1):254-64. DOI: 10.1148/radiol.13112553. View

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

10.

Mun M, Kohno T . Efficacy of thoracoscopic resection for multifocal bronchioloalveolar carcinoma showing pure ground-glass opacities of 20 mm or less in diameter. J Thorac Cardiovasc Surg. 2007; 134(4):877-82. DOI: 10.1016/j.jtcvs.2007.06.010. View

11.

Lu C, Hsiao C, Chang Y, Lee J, Shih J, Wu L . Percutaneous computed tomography-guided coaxial core biopsy for small pulmonary lesions with ground-glass attenuation. J Thorac Oncol. 2011; 7(1):143-50. DOI: 10.1097/JTO.0b013e318233d7dd. View

12.

Aoki T, Nakata H, Watanabe H, Nakamura K, Kasai T, Hashimoto H . Evolution of peripheral lung adenocarcinomas: CT findings correlated with histology and tumor doubling time. AJR Am J Roentgenol. 2000; 174(3):763-8. DOI: 10.2214/ajr.174.3.1740763. View

13.

Haro A, Yano T, Kohno M, Yoshida T, Okamoto T, Maehara Y . Ground-glass opacity lesions on computed tomography during postoperative surveillance for primary non-small cell lung cancer. Lung Cancer. 2011; 76(1):56-60. DOI: 10.1016/j.lungcan.2011.09.002. View

14.

Aoki T, Tomoda Y, Watanabe H, Nakata H, Kasai T, Hashimoto H . Peripheral lung adenocarcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival. Radiology. 2001; 220(3):803-9. DOI: 10.1148/radiol.2203001701. View

15.

Sakamoto H, Shimizu J, Horio Y, Ueda R, Takahashi T, Mitsudomi T . Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J Pathol. 2007; 212(3):287-94. DOI: 10.1002/path.2165. View

16.

Yoshida J, Nagai K, Yokose T, Nishimura M, Kakinuma R, Ohmatsu H . Limited resection trial for pulmonary ground-glass opacity nodules: fifty-case experience. J Thorac Cardiovasc Surg. 2005; 129(5):991-6. DOI: 10.1016/j.jtcvs.2004.07.038. View

17.

Nakao M, Yoshida J, Goto K, Ishii G, Kawase A, Aokage K . Long-term outcomes of 50 cases of limited-resection trial for pulmonary ground-glass opacity nodules. J Thorac Oncol. 2012; 7(10):1563-6. DOI: 10.1097/JTO.0b013e3182641b5c. View

18.

Hasegawa M, Sone S, Takashima S, Li F, Yang Z, Maruyama Y . Growth rate of small lung cancers detected on mass CT screening. Br J Radiol. 2001; 73(876):1252-9. DOI: 10.1259/bjr.73.876.11205667. View

19.

Kodama K, Higashiyama M, Yokouchi H, Takami K, Kuriyama K, Kusunoki Y . Natural history of pure ground-glass opacity after long-term follow-up of more than 2 years. Ann Thorac Surg. 2002; 73(2):386-92; discussion 392-3. DOI: 10.1016/s0003-4975(01)03410-5. View

20.

Ashizawa K, Maruyama Y, Kobayashi T, Kondo T, Nakagawa T, Hatakeyama M . Guidelines for the management of pulmonary nodules detected by low-dose CT lung cancer screening 6th edition: compiled by the Japanese Society of CT Screening. Jpn J Radiol. 2024; 43(3):333-346. PMC: 11868311. DOI: 10.1007/s11604-024-01695-0. View